Abstract
Primary immune thrombocytopenia (ITP) is an autoimmune disorder characterized by isolated thrombocytopenia due to accelerated platelet destruction and impaired platelet production. Diagnosis of ITP is still challenging because ITP has been diagnosed by exclusion. Exclusion of thrombocytopenia due to bone marrow failure is especially important in Japan because of high prevalence of aplastic anemia compared to Western countries. Hence, we propose a new diagnostic criteria involving the measurement of plasma thrombopoietin (TPO) levels and percentage of immature platelet fraction (RP% or IPF%); 1) isolated thrombocytopenia with no morphological evidence of dysplasia in any blood cell type in a blood smear, 2) normal or slightly increased plasma TPO level (< cutoff), 3) elevated RP% or IPF% (> upper limit of normal), and 4) absence of other conditions that potentially cause thrombocytopenia including secondary ITP. A diagnosis of ITP is made if conditions 1-4 are all met. Cases in which criterion 2 or 3 is not met or unavailable are defined as “possible ITP,” and diagnosis of ITP can be made mainly by typical clinical course. These new criteria enable us to clearly differentiate ITP from aplastic anemia and other forms of hypoplastic thrombocytopenia and can be highly useful in clinical practice for avoiding unnecessary bone marrow examination as well as for appropriate selection of treatments.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Kuwana, Masataka 2 ; Murata, Mitsuru 3 ; Shimada, Naoki 4 ; Takafuta, Toshiro 5 ; Yamanouchi, Jun 6 ; Kato, Hisashi 7 ; Hato, Takaaki 8 ; Tomiyama, Yoshiaki 7 1 Osaka University Hospital, Department of Blood Transfusion, Suita, Japan (GRID:grid.412398.5) (ISNI:0000 0004 0403 4283)
2 Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan (GRID:grid.410821.e) (ISNI:0000 0001 2173 8328)
3 International University of Health and Welfare, Center for Clinical Medical Research, Ohtawara, Tochigi, Japan (GRID:grid.411731.1) (ISNI:0000 0004 0531 3030)
4 International University of Health and Welfare, Center for Basic Medical Research, Ohtawara, Tochigi, Japan (GRID:grid.411731.1) (ISNI:0000 0004 0531 3030)
5 Hiroshima City Funairi Citizens Hospital, Department of Internal Medicine, Hiroshima, Hiroshima, Japan (GRID:grid.411731.1)
6 Ehime University Hospital, Division of Blood Transfusion and Cell Therapy, Toon, Ehime, Japan (GRID:grid.452478.8) (ISNI:0000 0004 0621 7227)
7 Osaka University, Department of Hematology and Oncology, Graduate School of Medicine, Suita, Osaka, Japan (GRID:grid.136593.b) (ISNI:0000 0004 0373 3971)
8 Japanese Red Cross Ehime Blood Center, Matsuyama, Ehime, Japan (GRID:grid.410775.0) (ISNI:0000 0004 1762 2623)





